Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.

2478 Street City Ohio 90255

info@mediax.com

+(402) 763 282 46

Let’s Stay In Touch

Shopping cart

Subtotal $0.00

View cartCheckout

Appointment Now

Medical Treatment Plan for Stage III Colon Cancer with Intra-abdominal Lesions

  • Home
  • Medical Treatment Plan for Stage III Colon Cancer with Intra-abdominal Lesions
All Treatments Services
Contact Us

Overview

This medical treatment plan is designed for a patient diagnosed with Stage III colon cancer (T3 N2 M0), with a primary large mass in the colon and multiple small lesions in the colon, rectum, and stomach. The treatment approach focuses on local control of the disease through Transcatheter Arterial Chemoembolization (TACE) for the large mass, followed by dendritic cell therapy to address the multiple smaller lesions within the gastrointestinal tract. Additionally, WEGOVITA’s specialized medical services are incorporated to ensure a comprehensive and individualized approach, providing access to advanced treatment options and personalized care throughout the patient’s journey.

Treatment Objectives

1. Primary Objective:

  • Control and potentially reduce the large tumor mass in the colon, achieving local tumor control and preventing further progression.

2. Secondary Objective:

  • Immunological modulation using dendritic cell therapy to enhance the body’s anti-tumor immune response, addressing micrometastatic disease and reducing the presence of multiple small lesions in the colon, rectum, and stomach.

Proposed Therapeutic Approach:

1. Transcatheter Arterial Chemoembolization (TACE) for Large Mass

Indication :
  • The patient has a large primary mass in the colon, which will be treated with TACE to achieve tumor reduction and improve symptoms.
Procedure Details:Pre-procedural Imaging:
  • Obtain contrast-enhanced CT or MRI to assess the location, size, and blood supply of the tumor. This is crucial for planning the catheter placement.
Procedure Technique:

 Under fluoroscopic guidance, a catheter is inserted into the femoral artery and advanced to the vascular supply of the tumor.

 The chemotherapy agent (e.g., doxorubicin or cisplatin) is then delivered directly to the tumor bed via the catheter.

 The tumor is embolized using particles such as microspheres or other embolic agents to block the blood supply, thereby trapping the chemotherapeutic agent within the tumor.

Post-procedural Care:

 The patient will require close monitoring in a post-procedure observation area for any complications, such as pain, fever, or gastrointestinal bleeding.

  Pain management may include acetaminophen or opioids if needed for severe discomfort.

  A follow-up imaging study will be performed within 4-6 weeks to assess the response to treatment, including the degree of necrosis and shrinkage of the mass.

2. Dendritic Cell Therapy (Immunotherapy)

Indication :

  • Dendritic cell therapy will be initiated due to the presence of multiple small lesions in the colon, rectum, and stomach. The aim is to utilize the patient’s own immune system to target and destroy cancer cells.

Procedure Details:Cell Preparation:

  • Dendritic cells will be isolated from the patient’s peripheral blood or bone marrow.
  • The dendritic cells will be cultured and activated ex vivo by exposing them to cancer antigens derived from the patient’s tumor tissue.

Immunization Schedule:

  •  Once the dendritic cells are fully activated, they will be re-infused into the patient through subcutaneous or intravenous injection.
  •  The patient will undergo multiple cycles of dendritic cell vaccination, typically over the course of several weeks to months, depending on their clinical response.

Post-therapy Monitoring:

  •  Immune response will be monitored through regular blood tests, including flow cytometry to assess T-cell activation and cytokine levels.
  •  Imaging (CT or MRI) will be performed after each cycle to evaluate the efficacy of the immunotherapy and monitor the size of the small lesions in the colon, rectum, and stomach.

3. Adjuvant Chemotherapy and Radiation Therapy (if necessary)

Chemotherapy Regimen (FOLFOX or FOLFIRI):
Given the stage of the disease (Stage III), adjuvant chemotherapy is typically recommended to reduce the risk of recurrence.
FOLFOX (Fluorouracil, Leucovorin, Oxaliplatin):
  •  Infusion of fluorouracil (5-FU) combined with leucovorin, along with oxaliplatin, will be administered every two weeks for six cycles.
  •  Chemotherapy will be adjusted based on the patient’s tolerance and adverse effects.
FOLFIRI (Fluorouracil, Leucovorin, Irinotecan):
  •  If the FOLFOX regimen is poorly tolerated or there is disease progression, an alternative chemotherapy regimen, such as FOLFIRI, may be utilized.
Radiation Therapy (if needed):
  •  If there is significant local involvement or peritoneal metastasis, radiation therapy may be considered to control local disease.
  •  The patient will undergo a detailed planning CT scan to map out the radiation fields, ensuring minimal radiation exposure to adjacent healthy tissues.

Supportive Care and Management

1. Nutritional Support:

  •  A referral to a dietitian will be made to ensure proper nutritional intake, as the patient may experience gastrointestinal symptoms related to both the cancer and its treatment.
  •  Nutritional supplements and a high-calorie, high-protein diet may be recommended to support the immune system and overall health.

2. Pain Management:

  •  Acute Pain Management: Pain related to the large tumor mass will be managed with analgesics (NSAIDs or opioids as needed).
  •  Chronic Pain Management: For ongoing pain, adjuvant treatments such as nerve blocks or alternative therapies may be considered.

3. Psychosocial Support:

  •  A referral to a counselor or oncology support group is recommended to help the patient cope with the emotional and psychological stresses associated with cancer treatment.

Monitoring and Follow-up

Oncology Follow-up:
  •  The patient will be monitored regularly by oncology for signs of recurrence or progression. Follow-up visits will be scheduled every 3 months for the first 2 years and every 6 months thereafter.
Imaging Follow-up:
  •  Ongoing imaging will be performed at regular intervals, depending on the patient’s clinical response.

Prognosis

 Prognosis for patients with Stage III colon cancer is variable, and it will depend on tumor response to the treatments, including TACE and dendritic cell therapy. The expected benefit from dendritic cell therapy is to reduce the potential for micrometastatic disease progression, while TACE offers targeted treatment for the primary mass. The services of WEGOVITA will also provide the patient with advanced medical oversight and access to specialized resources, which may contribute positively to the overall treatment outcome.

Conclusion

 This treatment plan is designed to address both the primary large mass and the multiple small lesions present in the colon, rectum, and stomach. The combination of TACE for localized treatment and dendritic cell therapy for immunological targeting is a comprehensive approach aimed at controlling tumor burden and improving the patient’s long-term survival outcomes.

Personalized Medical Evaluation

 If you or a loved one is facing advanced or progressive colon cancer, we understand how overwhelming the journey can be. At WEGOVITA, we are committed to prepare for you the most personalized, compassionate care to navigate this challenge. We encourage you to submit your medical reports for a thorough evaluation, where our team of specialists will provide a tailored assessment.

Our goal is to connect you with the right doctor, hospital, and a customized treatment plan that fits your unique needs. Each case is different, and we understand that personalized care is the key to optimizing outcomes. Through this service, you will receive:

  A personalized medical evaluation by top specialists in the field.

  A carefully selected medical team and hospital tailored to your specific condition.

  An individualized pricing plan based on your medical case and stage ensuring transparency and confidence in your treatment journey.

Your health and well-being are our priority, and we are here to support you every step of the way. Take the first step toward hope and healing—submit your medical reports today, and allow us to assist you in finding the right path forward


💡Important for You

WEGOVITA offers medical coordination services by connecting international patients with top hospitals and specialists across Germany. We support access to expert evaluations, facilitate treatment logistics, and present a range of available medical options.

However, WEGOVITA does not provide direct medical treatment, make medical diagnoses, or recommend specific therapies. All final medical decisions—including diagnosis, treatment planning, and cost—are made solely by licensed medical professionals after a full clinical assessment of the individual patient.

This information is provided for informational purposes, based on internationally recognized guidelines and practices used in Germany’s leading medical institutions. It is not a substitute for professional medical advice.

💡 Interested in clinical trial references, treatment innovations, or cost comparisons? Contact our medical coordination team at info@wegovita.com for personalized assistance.

Your Health. Your Journey. With WEGOVITA.